Lyumjev OK'd for Kids; Sand for Weight Loss? AGA's New Obesity Guidelines
(MedPage Today) -- The FDA expanded the indication for rapid-acting mealtime insulin lispro-aabc (Lyumjev) to now also include children ages 1 year and older with diabetes, based on the phase III PRONTO-Peds trial, Eli Lilly announced.
Estimating...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Children | Diabetes | Eating Disorders & Weight Management | Endocrinology | Humalog | Insulin | Obesity | Weight Loss